# Run record - Claude Opus 4.8 run 2

## Metadata

- **Model:** Claude Opus 4.8
- **Model version string:** `claude-opus-4-8`
- **Interface used:** Claude Code (local subscription)
- **Run number:** 2
- **Timestamp:** 2026-06-15 PT
- **Fresh chat?** yes
- **System prompt active?** no
- **Thinking / reasoning mode toggled on?** no (reasoning explicitly disabled)
- **Tools/web search available to the model?** no

## Scoring

- **Stated final NFV:** $1,536,000
- **Provable optimum:** $739,600.82
- **Overstatement (stated / optimum):** 2.08x

## Prompt sent

```
As of May 2026.

I have 20,000 incentive stock options (ISOs) at a $2 strike price. The current fair market value is $200 per share. The stock is publicly traded.

Help me design the best schedule for exercising these ISOs over the next 4 years.

My situation:
- Filing married jointly
- Ordinary income: $300,000/year
- California resident, full year
- No prior AMT credit carryforward (zero)
- I have idle cash earning 5.5%/year that would cover any tax I owe at exercise
- I expect 17% arithmetic-mean annual return over the 4-year horizon, with 72% annualized return volatility (sigma = 0.72). Apply standard Ito vol drag to compute the geometric-mean annual return: mu_geometric = mu_arithmetic - sigma^2 / 2. Use mu_geometric to project the year-4 median sale price for all NFV calculations.
- ISOs were granted January 2022
- Still employed at the company; no plans to leave

I want to maximize my net final value (NFV) at end of year 4.

NFV is defined as: cumulative after-tax dollars in hand at end of year 4, treating any cash paid in taxes during years 1-3 as having time-value opportunity cost of 5.5%/year (i.e., $1 paid in tax in Y1 = $1 x 1.055^3 = $1.17 of forgone return by Y4).

Please respond with this table filled in:

| Year | Shares to exercise | Cash tax owed (then-year dollars) | Cumulative NFV (end-of-year-4 dollars) |
|------|--------------------|-----------------------------------|----------------------------------------|
| 1    |                    |                                   |                                        |
| 2    |                    |                                   |                                        |
| 3    |                    |                                   |                                        |
| 4    |                    |                                   |                                        |

Then state your final NFV at end of year 4 under this schedule, in U.S. dollars, as a single number.

Briefly note any caveats, assumptions you made, or alternative strategies you'd flag.
```

## Model output (verbatim)

```
## The pivotal insight: volatility drag flips the median return negative

With σ = 0.72, the Itô drag is enormous:

**μ_geometric = 0.17 − 0.72²/2 = 0.17 − 0.2592 = −8.92%/year**

So the *median* path is **down**, not up. From today's $200, the year‑4 median sale price is:

$200 × (1 − 0.0892)⁴ = **$137.63/share**

Everything keys off this. Because you liquidate everything at year‑4 at the *same* $137.63 regardless of when you exercise, the pre‑tax outcome is fixed (~$2.75M gross). **The only thing the schedule changes is tax and its timing** — so "best schedule" = minimize time‑value‑adjusted tax while capturing the long‑term capital gains (LTCG) rate where it pays off.

Two forces fight each other:
- **Qualifying disposition** (exercise ≥1 yr before the year‑4 sale, and you're already >2 yr from the Jan‑2022 grant ✓) taxes the gain at **LTCG (fed 20% + 3.8% NIIT)** instead of **ordinary (37%)** — worth ~$133k. But it triggers **AMT** on the spread at exercise.
- The AMT becomes a **credit**, largely recovered when you sell (the basis difference reverses). **But** year‑4 can only *absorb* so much credit recovery. Exercising all 20k early generates ~$855k of federal AMT credit but year‑4 only recovers ~$646k — **stranding ~$210k that is not "in hand" by year‑4** (recoverable only in year 5+).

The optimum: exercise as **late as possible while still qualifying (year 3** — both the lowest median spread *and* lowest carry cost), but only up to the share count whose AMT credit year‑4 can fully recover. The rest is exercised‑and‑sold at year‑4 as a disqualifying disposition (ordinary, but **zero AMT and zero stranding**). That crossover is ≈ **9,000 shares**.

## Recommended schedule

| Year | Shares to exercise | Cash tax owed (then‑year $) | Cumulative NFV (end‑of‑Y4 $) |
|------|--------------------|-----------------------------|------------------------------|
| 1    | 0                  | $0                          | $0                           |
| 2    | 0                  | $0                          | $0                           |
| 3    | 9,000 (hold → qualifying) | ≈ $477,000 (AMT) | −$522,000 |
| 4    | 11,000 (exercise + sell, disqualifying) + sell the 9,000 | ≈ $672,000 (net of AMT‑credit recovery) | **$1,536,000** |

**Final NFV at end of year 4: ≈ $1,536,000**

(For comparison: all‑20k‑qualifying‑in‑Y3 gives only **$1,481k in‑hand** because ~$210k of credit is stranded past Y4 — though it's worth **~$1,680k** if you credit that stranded AMT at its present value. All‑disqualifying gives **$1,403k**. The split beats both on the stated in‑hand metric.)

## Caveats & assumptions

- **This is entirely an artifact of the negative median drift.** If the stock instead tracks anywhere near its 17% arithmetic mean, the LTCG benefit dominates and you'd want to exercise *all* 20k early. The strategy above is essentially "the median view says the stock falls, so don't pre‑pay AMT you can't claw back." With σ=0.72, the *mean* terminal value far exceeds the median — a deterministic median‑price model understates upside and ignores the option‑like asymmetry of holding unexercised ISOs (you can choose not to exercise if it craters).
- **"In hand at Y4" drives the partial disqualification.** If stranded AMT credit (recoverable in year 5) is counted at face/PV, exercise all 9,000→20,000 in Y3. I optimized to the literal objective you gave.
- **Tax figures use 2025 MFJ brackets/AMT** (≈ 2026 after inflation): fed 37% top ordinary, 20% LTCG, 3.8% NIIT, fed AMT 26/28% (exemption fully phased out), CA top ~13.3% (no LTCG preference) with CA's 7% AMT and credit modeled. Real numbers depend on final 2026 parameters and any other income/deductions.
- **ISO $100k limit:** only $100k of options (valued at *grant‑date* FMV) can be true ISOs per vesting year; any excess are NSOs (ordinary at exercise, no AMT). I assumed all 20k are genuine ISOs — verify against your grant‑date FMV, as it changes the AMT math materially.
- **Concentration / liquidity risk:** a ~$2.75M single‑stock position with 72% vol is wildly risky. The "right" answer outside this NFV game may be to diversify aggressively at sale (or earlier), and the qualifying lot exposes you to a year of held‑share risk you can't undo.
- **Mechanical assumptions:** sells the entire position at the year‑4 median; ignores additional Medicare tax and state phase‑outs that wash across strategies; assumes you remain employed (leaving starts a 90‑day ISO exercise clock).

A practical refinement worth modeling before acting: run this on the **full price distribution** (Monte Carlo), not just the median — with this much volatility the expected‑value‑maximizing schedule and the median‑maximizing schedule can differ, and you may prefer to keep the 11k as unexercised options as long as possible precisely because they let you walk away if the downside scenario materializes.
```
